Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Rhythm Pharmaceuticals, Inc.

RYTM ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Pharmaceuticals ·

USA Mid Cap Analyst: BUY

Last Close

$99.02

▲ +1.03%

Market Cap $6.82B · Vol 170.68K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$6.82B

Mid Cap

Div Yield

N/A

EPS Growth

+3.52%

YoY

RSI (14)

24.67

Momentum

Beta

2.01

vs Market

52W High

$122.06

19.70% below

52W Low

$75.00

30.68% above

Volume

170.68K

Avg 181.66K

P/B

51.73

Price-to-book

ROE

-92.93%

Return on equity

Free Float

95.00%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Rhythm Pharmaceuticals, Inc. (RYTM) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does RYTM pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-3.11%

-14.22%

+3.33%

+12.93%

YTD

-7.49%

+3.04%

+296.71%

+645.07%

Financials & Valuation

TTM · Annual

Total Revenue	$189.76M
Net Income	$-196,539,000.00
Revenue Growth (YoY)	+46.91%
Gross Margin	89.73%
Operating Margin	-101.19%
Net Profit Margin	-103.57%
ROE	-92.93%
ROA · ROIC	-44.94% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	36.66
P/B	51.73
P/FCF	N/A
EPS Growth	+3.52%
Outstanding Shares	68.85M

Technical Indicators

50-Day SMA	$107.71
200-Day SMA	$99.43
RSI (14)	24.67
Beta	2.01
52-Week High	$122.06
52-Week Low	$75.00

Volume Today	170.68K
Avg Daily Volume (30D)	181.66K
Relative Volume	0.94x
Volatility (10D)	35.01
Volatility (30D)	36.05
Free Float	95.00%

Analyst Consensus

BUY

Current Price $99.02

Mean Target $138.13

52W Low$75.00 52W High$122.06

Current

Target

$75.00 $122.06

Current Analyst target

+39.49% upside potential · 17 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG007DLZ629

ISINUS76243J1051

CountryUSA

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeADR American Depositary Receipt

Similar Halal Stocks

LLY Eli Lilly and Company +1.28% JNJ Johnson & Johnson +1.10% ABBV AbbVie Inc. +0.58% NVS Novartis AG +1.60% NOVN.S Novartis AG +1.52%

Company Profile

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's lead asset, IMCIVREE, is an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the Food and Drug Administration (FDA) to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged four years and older with acquired hypothalamic obesity, adult and pediatric patients two years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. In addition to it the Company is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism.